Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104675 · ClinicalTrials.gov registry record · Phase 2
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 study of Ovarian Cancer and Peritoneal Cancer, sponsored by CASI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT01104675 is a Phase 2 study of Ovarian Cancer and Peritoneal Cancer that has completed, run by CASI Pharmaceuticals. The registered enrollment target is 64 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT01104675, a Phase 2 study of Ovarian Cancer and Peritoneal Cancer, has completed, sponsored by CASI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Conditions Studied
Interventions
- DRUG ENMD-2076
Study Locations (6)
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Massachusetts
- Dana Farber/Partners Cancer Care - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104675
The ClinicalTrials.gov registry entry for NCT01104675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (91% lower). The listed sponsor is CASI Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which ENMD-2076 is the first listed.
NCT01104675 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Illinois, Indiana.
Frequently Asked Questions
What is clinical trial NCT01104675 about?
NCT01104675 is a clinical study titled "Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer". The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
What is the current status of trial NCT01104675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-04. Estimated completion is 2012-12.
What conditions does trial NCT01104675 study?
This clinical trial studies the following conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Cancer.
What interventions are being tested in trial NCT01104675?
The interventions under investigation include: ENMD-2076 (DRUG).
Who is sponsoring clinical trial NCT01104675?
This trial is sponsored by CASI Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01104675 being conducted?
This trial has 6 study locations across Colorado, Illinois, Indiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.